HACKENSACK, N.J., July 12, 2016 (GLOBE NEWSWIRE) -- Brainsway® USA Inc., a leader in the treatment of brain disorders, announced today that it has moved its U.S. headquarters to Hackensack, New Jersey. Brainsway’s move to the greater New York metropolitan area comes on the heels of its highest revenue generating quarter in its history. The company makes the relocation from its original headquarters in Philadelphia.
“Placing our U.S. Headquarters in the largest metro area in the U.S. signifies our commitment to continued investment in the U.S. market. Furthermore, this move gives us a stronger national presence, allowing us increased access to better service our customers across the country,” said Joseph Perekupka, VP of North American Sales Operations. “Deep TMS is now used in 40 states across the country, having gained significant traction since our U.S. launch at the end of 2014. We’re very excited to bring our headquarters to this dynamic market.”
Greater New York was selected due to the region’s foothold in healthcare coupled with its advanced business ecosystem. Brainsway will continue to expand, as it grows its staff in order to strengthen the companies’ services – everything from client services to tech support.
Developed in conjunction with the NIH, Brainsway Systems are now deployed in major academic centers and U.S. military institutions across the country. Deep TMS – a helmet that sends magnetic fields into the brain to non-invasively provide relief – is being used by some of the top physicians in the U.S. Resistance to treatment has been a growing concern, affecting up to half of the 15 million Americans suffering from depression. As such, the medical community has expressed a significant need for Deep TMS.
For more information on Brainsway and to find the nearest Deep TMS provider, please visit www.brainsway.com.
Brainsway Ltd. is a leader in non-invasive treatments for brain disorders utilizing Deep Transcranial Magnetic Stimulation (Deep TMS). Our unique patented technology was developed in collaboration with the National Institute of Health (NIH) and is FDA and CE cleared to treat patients with depression who are not currently responding to medication. The treatment has been enthusiastically supported by many academic communities and is widely covered by most insurance payers. For more information, please visit www.brainsway.com.
Media Contact: Megan Vandenbos firstname.lastname@example.org 201-465-8019